相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Evaluation of retinal inflammatory biomarkers after intravitreal steroid implant and Ranibizumab injection in diabetic macular edema
Ilkay Kilic Muftuoglu et al.
EUROPEAN JOURNAL OF OPHTHALMOLOGY (2022)
Risk of stroke associated with intravitreal ranibizumab injections in age-related macular degeneration: a nationwide case-crossover study
Jiwon Kim et al.
EYE (2021)
Intravitreal ranibizumab and dexamethasone implant injections as primary treatment of diabetic macular edema: simultaneously double protocol
Mahmut Kaya et al.
EYE (2021)
Anti-VEGF Therapy Reduces Inflammation in Diabetic Macular Edema
Makoto Imazeki et al.
OPHTHALMIC RESEARCH (2021)
Macular microvascular changes after intravitreal bevacizumab injection in diabetic macular edema
Reza Mirshahi et al.
CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE (2021)
The Impact of Race on Short-term Treatment Response to Bevacizumab in Diabetic Macular Edema
Pawarissara Osathanugrah et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2021)
Risk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice
Maya H. Maloney et al.
OPHTHALMOLOGY (2021)
Aflibercept versus Ranibizumab as a Second Line Therapy After Bevacizumab for Diabetic Macular Edema
Nasser G. Alsaedi et al.
CLINICAL OPHTHALMOLOGY (2021)
Effect of dexamethasone intravitreal implant for refractory and treatment-naive diabetic macular edema in Taiwanese patients
Jia-Kang Wang et al.
JOURNAL OF THE CHINESE MEDICAL ASSOCIATION (2021)
Intravitreal Dexamethasone Implant versus Intravitreal Ranibizumab Injection for Treatment of Non-Proliferative Diabetic Macular Edema: A Prospective, Randomized and Blinded Trial
Sanjay Kumar Mishra et al.
CURRENT DRUG DELIVERY (2021)
Bevacizumab induces oxidative cytotoxicity and apoptosis via TRPM2 channel activation in retinal pigment epithelial cells: Protective role of glutathione
Dilek Ozkaya et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2021)
Off-label intravitreal brolucizumab for recalcitrant diabetic macular edema: A real-world case series
Debdulal Chakraborty et al.
American Journal of Ophthalmology Case Reports (2021)
Association Between First- and Third-Month Responses to Intravitreal Ranibizumab for Diabetic Macular Edema
Diego Alejandro Valera-Cornejo et al.
JOURNAL OF VITREORETINAL DISEASES (2021)
Foveal Eversion: A Possible Biomarker of Persistent Diabetic Macular Edema
Alessandro Arrigo et al.
OPHTHALMOLOGY AND THERAPY (2021)
Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis
Bernardete Pessoa et al.
CLINICAL OPHTHALMOLOGY (2021)
Early versus late switch: How long should we extend the anti-vascular endothelial growth factor therapy in unresponsive diabetic macular edema patients?
Adrian Hernandez Martinez et al.
EUROPEAN JOURNAL OF OPHTHALMOLOGY (2020)
Ranibizumab Alters Levels of Intraocular Soluble Cytokine Receptors in Patients with Diabetic Macular Edema
Brandon A. Coughlin et al.
CURRENT EYE RESEARCH (2020)
Serum pro-inflammatory factors as predictors of persistent diabetic macular oedema with limited anatomic response to anti-VEGF: association with intravitreal injection treatment profiles in real-world setting
Pedro Brito et al.
ACTA OPHTHALMOLOGICA (2020)
Effect of Intravitreal Ranibizumab on Intraretinal Hard Exudates in Eyes with Diabetic Macular Edema
Sowmya Srinivas et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2020)
The Short-Term Efficacy of Biweekly Subconjunctival Bevacizumab in Diabetic Macular Edema
Volkan Yeter et al.
CURRENT EYE RESEARCH (2020)
Ranibizumab or Aflibercept for Diabetic Macular Edema Comparison of 1-Year Outcomes from the Fight Retinal Blindness! Registry
Sanjeeb Bhandari et al.
OPHTHALMOLOGY (2020)
Efficacy of Conversion to Aflibercept for Diabetic Macular Edema Previously Refractory to Bevacizumab or Ranibizumab: A Meta-analysis of High-Quality Nonrandomized Studies
Kang Xiao et al.
ANNALS OF PHARMACOTHERAPY (2020)
Inhibition of Sema4D/PlexinB1 signaling alleviates vascular dysfunction in diabetic retinopathy
Jie-hong Wu et al.
EMBO MOLECULAR MEDICINE (2020)
Use of biomaterials for sustained delivery of anti-VEGF to treat retinal diseases
Ivan Seah et al.
EYE (2020)
A Randomized, Double-Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Patients with Visual Impairment due to Diabetic Macular Edema (KITE)
Justus G. Garweg
KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE (2020)
RETINAL LEAKAGE INDEX DYNAMICS ON ULTRA-WIDEFIELD FLUORESCEIN ANGIOGRAPHY IN EYES TREATED WITH INTRAVITREAL AFLIBERCEPT FOR PROLIFERATIVE DIABETIC RETINOPATHY IN THE RECOVERY STUDY
Amy S. Babiuch et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2020)
Combination of Intravitreal Bevacizumab and Topical Dorzolamide versus Intravitreal Bevacizumab Alone for Diabetic Macular Edema: A Randomized Contralateral Clinical Trial
Farhad Fazel et al.
BIOMED RESEARCH INTERNATIONAL (2020)
Hyperreflective Walls in Foveal Cystoid Spaces as a Biomarker of Diabetic Macular Edema Refractory to Anti-VEGF Treatment
Noriko Terada et al.
SCIENTIFIC REPORTS (2020)
Evaluation of Changes in Macular Perfusion Detected by Optical Coherence Tomography Angiography following 3 Intravitreal Monthly Bevacizumab Injections for Diabetic Macular Edema in the IMPACT Study
Ayman G. Elnahry et al.
JOURNAL OF OPHTHALMOLOGY (2020)
Intravitreal Ziv-Aflibercept in Patients With Diabetic Macular Edema Refractory to Intravitreal Bevacizumab
Nazanin Ebrahimiadib et al.
OPHTHALMIC SURGERY LASERS & IMAGING RETINA (2020)
Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study)
Adam R. Glassman et al.
OPHTHALMOLOGY (2020)
Persistent or Recurrent Diabetic Macular Edema After Fluocinolone Acetonide 0.19 mg Implant: Risk Factors and Management
Maria Vittoria Cicinelli et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2020)
Eicosanoids and Oxidative Stress in Diabetic Retinopathy
Mong-Heng Wang et al.
ANTIOXIDANTS (2020)
The Application of Structural Retinal Biomarkers to Evaluate the Effect of Intravitreal Ranibizumab and Dexamethasone Intravitreal Implant on Treatment of Diabetic Macular Edema
Ida Ceravolo et al.
DIAGNOSTICS (2020)
Pattern recognition receptor-mediated inflammation in diabetic vascular complications
Xu Wang et al.
MEDICINAL RESEARCH REVIEWS (2020)
VEGF is an autocrine/paracrine neuroprotective factor for injured retinal ganglion neurons
Nicolas Froger et al.
SCIENTIFIC REPORTS (2020)
Risk factors for an atherothrombotic event in patients with diabetic macular edema treated with intravitreal injections of bevacizumab
Alon Tiosano et al.
INTERNATIONAL JOURNAL OF OPHTHALMOLOGY (2020)
Effect of Adding Losartan to Bevacizumab for Treating Diabetic Macular Edema
Fariba Ghassemi et al.
JOURNAL OF OPHTHALMOLOGY (2020)
Comparing the Efficacy of Bevacizumab and Ranibizumab in Patients with Diabetic Macular Edema (BRDME) The BRDME Study, a Randomized Trial
Maartje J. C. Vader et al.
OPHTHALMOLOGY RETINA (2020)
Differential response to intravitreal dexamethasone implant in naive and previously treated diabetic macular edema eyes
Javier Zarranz-Ventura et al.
BMC OPHTHALMOLOGY (2020)
Intravitreal injections of bevacizumab plus methotrexate versus bevacizumab alone for the treatment of diabetic macular edema: A randomized, sham-controlled trial
Farhad Fazel et al.
JOURNAL OF CURRENT OPHTHALMOLOGY (2020)
Intravitreal bevacizumab-induced exacerbation of proteinuria in diabetic nephropathy, and amelioration by switching to ranibizumab
Ramy M. Hanna et al.
SAGE OPEN MEDICAL CASE REPORTS (2020)
Incidence and progression of diabetic retinopathy: a systematic review
Charumathi Sabanayagam et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Intravitreal injection of a Rho-kinase inhibitor (fasudil) combined with bevacizumab versus bevacizumab monotherapy for diabetic macular oedema: a pilot randomised clinical trial
Hamid Ahmadieh et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2019)
Randomised trial of wide-field guided PRP for diabetic macular oedema treated with ranibizumab
S. James Talks et al.
EYE (2019)
Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema BOULEVARD Phase 2 Randomized Trial
Jayashree Sahni et al.
OPHTHALMOLOGY (2019)
Aqueous Humor Cytokines and Long-Term Response to Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema
Tina Felfeli et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2019)
Preoperative Bevacizumab for Tractional Retinal Detachment in Proliferative Diabetic Retinopathy: A Prospective Randomized Clinical Trial
J. Fernando Arevalo et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2019)
Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis
Ba' Pham et al.
BMJ OPEN (2019)
Effect of Intravitreal Anti-Vascular Growth Factor Agents With or Without Macular Photocoagulation on Diabetic Macular Edema: A Systematic Review and Meta-Analysis
Lanjun Cui et al.
DIABETES THERAPY (2019)
Atrophy of the central neuroretina in patients treated for diabetic macular edema
Sonja G. Karst et al.
ACTA OPHTHALMOLOGICA (2019)
Aflibercept regulates retinal inflammation elicited by high glucose via the PlGF/ERK pathway
Francesca Lazzara et al.
BIOCHEMICAL PHARMACOLOGY (2019)
Spermine oxidase: A promising therapeutic target for neurodegeneration in diabetic retinopathy
S. Priya Narayanan et al.
PHARMACOLOGICAL RESEARCH (2019)
Association Between Change in Visual Acuity and Change in Central Subfield Thickness During Treatment of Diabetic Macular Edema in Participants Randomized to Aflibercept, Bevacizumab, or Ranibizumab: A Post Hoc Analysis of the Protocol T Randomized Clinical Trial
Neil M. Bressler et al.
JAMA OPHTHALMOLOGY (2019)
Combination of intravitreal bevacizumab and erythropoietin versus intravitreal bevacizumab alone for refractory diabetic macular edema: a randomized double-blind clinical trial
Morteza Entezari et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2019)
Reoperation following vitrectomy for diabetic vitreous hemorrhage with versus without preoperative intravitreal bevacizumab
Xuting Hu et al.
BMC OPHTHALMOLOGY (2019)
Factors Predicting Treatment Response in Anti-Vascular Endothelial Growth Factor Naive Diabetic Macular Edema Patients Treated with Intravitreal Bevacizumab
Alastair David Bezzina et al.
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS (2019)
Comparative effectiveness and harms of intravitreal antivascular endothelial growth factor agents for three retinal conditions: a systematic review and meta-analysis
Allison Low et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2019)
Cluster endophthalmitis due to Stenotrophomonas maltophilia following intravitreal bevacizumab: outcomes of patients from North India
Aniruddha Kishandutt Agarwal et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2019)
Soluble and membrane-bound adenylate kinase and nucleotidases augment ATP-mediated inflammation in diabetic retinopathy eyes with vitreous hemorrhage
Julian Zeiner et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2019)
Bevacizumab-associated glomerular microangiopathy
Fermin Person et al.
MODERN PATHOLOGY (2019)
One-Year Results of Using a Treat-and-Extend Regimen without a Loading Phase with Anti-VEGF Agents in Patients with Treatment-Naive Diabetic Macular Edema
Petra Schwarzer et al.
OPHTHALMOLOGICA (2019)
Intravitreal bevacizumab improves the clearance of vitreous haemorrhage and visual outcomes in patients with proliferative diabetic retinopathy
Joonas Wirkkala et al.
BMJ OPEN OPHTHALMOLOGY (2019)
Intravitreal bevacizumab versus ranibizumab: Effects on the vessels of the fellow non-treated eye
Mohammadreza Peyman et al.
JOURNAL OF CURRENT OPHTHALMOLOGY (2019)
Changes in aqueous concentrations of various cytokines after intravitreal bevacizumab and subtenon triamcinolone injection for diabetic macular edema
Seung-Young Yu et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2018)
Macular Structures, Optical Components, and Visual Acuity in Preschool Children after Intravitreal Bevacizumab or Laser Treatment
Yung-Sung Lee et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2018)
Mortality associated with bevacizumab intravitreal injections in age-related macular degeneration patients after acute myocardial infarct: a retrospective population-based survival analysis
Joel Hanhart et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2018)
Fewer Functional Deficits and Reduced Cell Death after Ranibizumab Treatment in a Retinal Ischemia Model
Marina Palmhof et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Serological inflammatory factors as biomarkers for anatomic response in diabetic macular edema treated with anti-VEGF
Pedro Brito et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2018)
The association between myocardial infarction and intravitreal bevacizumab injection
Jin-woo Kwon et al.
MEDICINE (2018)
Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy Factors Associated with Vision and Edema Outcomes
Susan B. Bressler et al.
OPHTHALMOLOGY (2018)
Anti-vascular endothelial growth factor for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trials
Chu Luan Nguyen et al.
BMC OPHTHALMOLOGY (2018)
Iron Overload Accelerates the Progression of Diabetic Retinopathy in Association with Increased Retinal Renin Expression
Kapil Chaudhary et al.
SCIENTIFIC REPORTS (2018)
Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-a-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease A Randomized Clinical Trial
Joseph Jankovic et al.
JAMA NEUROLOGY (2018)
Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema A DRCR Network Phase 2 Randomized Clinical Trial
Raj K. Maturi et al.
JAMA OPHTHALMOLOGY (2018)
Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment A Secondary Analysis of a Randomized Clinical Trial
Neil M. Bressler et al.
JAMA OPHTHALMOLOGY (2018)
Aqueous Humor Cytokine Levels and Anatomic Response to Intravitreal Ranibizumab in Diabetic Macular Edema
Roxane J. Hillier et al.
JAMA OPHTHALMOLOGY (2018)
Association of Changes in Macular Perfusion With Ranibizumab Treatment for Diabetic Macular Edema A Subanalysis of the RESTORE (Extension) Study
Sonja G. Karst et al.
JAMA OPHTHALMOLOGY (2018)
Early Response to Anti-Vascular Endothelial Growth Factor and Two-Year Outcomes Among Eyes With Diabetic Macular Edema in Protocol T
Neil M. Bressler et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2018)
Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy A Randomized Clinical Trial
Jeffrey G. Gross et al.
JAMA OPHTHALMOLOGY (2018)
The efficacy and safety of aflibercept and conbercept in diabetic macular edema
Siwei Cai et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2018)
Monthly Versus Treat-and-Extend Ranibizumab for Diabetic Macular Edema: A Prospective, Randomized Trial
David A. Eichenbaum et al.
OPHTHALMIC SURGERY LASERS & IMAGING RETINA (2018)
Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis
Gianni Virgili et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2018)
VEGF/VEGFR2 blockade does not cause retinal atrophy in AMD-relevant models'
Da Long et al.
JCI INSIGHT (2018)
Proteomic Analysis of Early Diabetic Retinopathy Reveals Mediators of Neurodegenerative Brain Diseases
Jeffrey M. Sundstrom et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2018)
Changes in Blood Pressure and Urine Albumin-Creatinine Ratio in a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema
Adam R. Glassman et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2018)
Predictive imaging biomarkers relevant for functional and anatomical outcomes during ranibizumab therapy of diabetic macular oedema
Bianca S. Gerendas et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2018)
Vitamin C preferentially kills cancer stem cells in hepatocellular carcinoma via SVCT-2
Hongwei Lv et al.
NPJ PRECISION ONCOLOGY (2018)
The Influence of Intravitreal Ranibizumab on Inflammation-associated Cytokine Concentrations in Eyes With Diabetic Macular Edema
Shueh Wen Lim et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2018)
VEGF regulates local inhibitory complement proteins in the eye and kidney
Lindsay S. Keir et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Intravitreal Diclofenac plus Bevacizumab versus Bevacizumab alone in treatment-naive diabetic macular edema: a randomized double-blind clinical trial
Heshmatollah Ghanbari et al.
INTERNATIONAL OPHTHALMOLOGY (2017)
Factors influencing intravitreal bevacizumab and triamcinolone treatment in patients with diabetic macular edema
Tai K. Kim et al.
EUROPEAN JOURNAL OF OPHTHALMOLOGY (2017)
The antibody aducanumab reduces Aβ plaques in Alzheimer's disease (vol 537, pg 50, 2016)
Jeff Sevigny et al.
NATURE (2017)
Randomized Trial of Treat and Extend Ranibizumab with and without Navigated Laser for Diabetic Macular Edema TREX-DME 1 Year Outcomes
John F. Payne et al.
OPHTHALMOLOGY (2017)
Protective effects on the retina after ranibizumab treatment in an ischemia model
Stephanie C. Joachim et al.
PLOS ONE (2017)
SERUM LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR BEFORE AND AFTER INTRAVITREAL INJECTION OF RANIBIZUMAB OR CONBERCEPT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Enzhong Jin et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2017)
SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB
Robert L. Avery et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2017)
VEGF production production and signaling in Muller glia are critical to modulating vascular function and neuronal integrity in diabetic retinopathy and hypoxic retinal vascular diseases
Yun-Zheng Le
VISION RESEARCH (2017)
Full-thickness macular hole formation following anti-VEGF injections for neovascular age-related macular degeneration
Stamatina A. Kabanarou et al.
CLINICAL INTERVENTIONS IN AGING (2017)
Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis
Seth R. Flaxman et al.
LANCET GLOBAL HEALTH (2017)
Use of Corticosteroids in the Treatment of Patients With Diabetic Macular Edema Who Have a Suboptimal Response to Anti-VEGF: Recommendations of an Expert Panel
Carl D. Regillo et al.
OPHTHALMIC SURGERY LASERS & IMAGING RETINA (2017)
Aqueous cytokine levels are associated with reduced macular thickness after intravitreal ranibizumab for diabetic macular edema
Tomoyasu Shiraya et al.
PLOS ONE (2017)
Characterization of liposomal carriers for the trans-scleral transport of Ranibizumab
Rini Rachel Joseph et al.
SCIENTIFIC REPORTS (2017)
Preoperative Bevacizumab Administration in Proliferative Diabetic Retinopathy Patients Undergoing Vitrectomy: A Randomized and Controlled Trial Comparing Interval Variation
Javier Castillo et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2017)
Role of the Fc Region in the Vitreous Half- Life of Anti-VEGF Drugs
Kwangsic Joo et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2017)
Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema
Sameh Mosaad Fouda et al.
CLINICAL OPHTHALMOLOGY (2017)
Comparative study of combined bevacizumab/targeted photocoagulation vs bevacizumab alone for macular oedema in ischaemic branch retinal vein occlusions
Yoko Tomomatsu et al.
ACTA OPHTHALMOLOGICA (2016)
Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab
L. C. Olmos et al.
EYE (2016)
Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Patient-Centered Outcomes From a Randomized Clinical Trial
Wesley T. Beaulieu et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2016)
Real-World Outcomes of Ranibizumab Treatment for Diabetic Macular Edema in a United Kingdom National Health Service Setting
Namritha V. Patrao et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2016)
Single- and repeated-dose toxicity study of bevacizumab, ranibizumab, and aflibercept in ARPE-19 cells under normal and oxidative stress conditions
Manuel Saenz-de-Viteri et al.
BIOCHEMICAL PHARMACOLOGY (2016)
Intravitreal bevacizumab for diabetic macular oedema: 5-year results of the Pan-American Collaborative Retina Study group
J. Fernando Arevalo et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2016)
Alterations in intraocular cytokine levels following intravitreal ranibizumab
Farzin Forooghian et al.
CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE (2016)
Involution patterns of retinopathy of prematurity after treatment with intravitreal bevacizumab: implications for follow-up
M. Isaac et al.
EYE (2016)
The Impact of Systemic Factors on Clinical Response to Ranibizumab for Diabetic Macular Edema
Rishi P. Singh et al.
OPHTHALMOLOGY (2016)
A Crossover Design for Comparative Efficacy A 36-Week Randomized Trial of Bevacizumab and Ranibizumab for Diabetic Macular Edema
Henry E. Wiley et al.
OPHTHALMOLOGY (2016)
Intravitreal Aflibercept for Diabetic Macular Edema 148-Week Results from the VISTA and VIVID Studies
Jeffrey S. Heier et al.
OPHTHALMOLOGY (2016)
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial
John A. Wells et al.
OPHTHALMOLOGY (2016)
INTRAVITREAL RANIBIZUMAB THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AND THE RISK OF STROKE A National Sample Cohort Study
Tyler Hyungtaek Rim et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2016)
Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema
John A. Wells et al.
JAMA OPHTHALMOLOGY (2016)
Cost-effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Treatment Analysis From the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial
Eric L. Ross et al.
JAMA OPHTHALMOLOGY (2016)
Aflibercept, bevacizumab and ranibizumab prevent glucose-induced damage in human retinal pericytes in vitro, through a PLA2/COX-2/VEGF-A pathway
Giovanni Giurdanella et al.
BIOCHEMICAL PHARMACOLOGY (2015)
Effect of High Glucose Levels on Amyloid β Production in Retinas of Spontaneous Diabetes Mellitus Otsuka Long-Evans Tokushima Fatty Rats
Noriaki Nagai et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2015)
Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer
A. J. Weickhardt et al.
BRITISH JOURNAL OF CANCER (2015)
Multiphasic changes in systemic VEGF following intravitreal injections of ranibizumab in a child
E. H. Shao et al.
EYE (2015)
Common pathophysiology affecting diabetic retinopathy and Parkinson's disease
Tian Tian et al.
MEDICAL HYPOTHESES (2015)
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema
John A. Wells et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Effects of Intravitreal Ranibizumab on Retinal Hard Exudate in Diabetic Macular Edema Findings from the RIDE and RISE Phase III Clinical Trials
Amitha Domalpally et al.
OPHTHALMOLOGY (2015)
Visual Impairment and Blindness Avoided with Ranibizumab in Hispanic and Non-Hispanic Whites with Diabetic Macular Edema in the United States
Rohit Varma et al.
OPHTHALMOLOGY (2015)
Long-term Effects of Therapy with Ranibizumab on Diabetic Retinopathy Severity and Baseline Risk Factors for Worsening Retinopathy
Michael S. Ip et al.
OPHTHALMOLOGY (2015)
A RANDOMIZED CONTROLLED TRIAL OF PANRETINAL PHOTOCOAGULATION WITH AND WITHOUT INTRAVITREAL RANIBIZUMAB IN TREATMENT-NAIVE EYES WITH NON-HIGH-RISK PROLIFERATIVE DIABETIC RETINOPATHY
Daniel A. Ferraz et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2015)
Full thickness macular hole case after intravitreal aflibercept treatment
Yuji Oshima et al.
BMC OPHTHALMOLOGY (2015)
Sustained intraocular VEGF neutralization results in retinal neurodegeneration in the Ins2Akita diabetic mouse
Jose R. Hombrebueno et al.
SCIENTIFIC REPORTS (2015)
Repeated Intravitreous Ranibizumab Injections for Diabetic Macular Edema and the Risk of Sustained Elevation of Intraocular Pressure or the Need for Ocular Hypotensive Treatment
Susan B. Bressler et al.
JAMA OPHTHALMOLOGY (2015)
Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial
Claus Zehetner et al.
ACTA OPHTHALMOLOGICA (2015)
Intravitreal pegaptanib for the treatment of ischemic diabetic macular edema
Christine A. Kiire et al.
CLINICAL OPHTHALMOLOGY (2015)
Serum and Plasma Vascular Endothelial Growth Factor Concentrations Before and After Intravitreal Injection of Aflibercept or Ranibizumab for Age-Related Macular Degeneration
Xiying Wang et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2014)
A Randomized Trial to Assess Functional and Structural Effects of Ranibizumab versus Laser in Diabetic Macular Edema (the LUCIDATE Study)
Oliver Comyn et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2014)
Neuronal Cell Death in the Inner Retina and the Influence of Vascular Endothelial Growth Factor Inhibition in a Diabetic Rat Model
Hae-Young Lopilly Park et al.
AMERICAN JOURNAL OF PATHOLOGY (2014)
Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture
Deepika Malik et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2014)
Ranibizumab and Risk of Hospitalisation for Ischaemic Stroke and Myocardial Infarction in Patients with Age-Related Macular Degeneration: A Self-Controlled Case-Series Analysis
Nicole L. Pratt et al.
DRUG SAFETY (2014)
Factors affecting visual outcomes in patients with diabetic macular edema treated with ranibizumab
R. Channa et al.
EYE (2014)
Association of retinal vessel calibre and visual outcome in eyes with diabetic macular oedema treated with ranibizumab
A. Moradi et al.
EYE (2014)
Intravitreal bevacizumab in the treatment of vasoproliferative retinal tumours
C. Rogers et al.
EYE (2014)
Fellow eye effect of unilateral intravitreal bevacizumab injection in eyes with diabetic macular edema
J. Hanhart et al.
EYE (2014)
Three-Year Outcomes of Individualized Ranibizumab Treatment in Patients with Diabetic Macular Edema: The RESTORE Extension Study
Ursula Schmidt-Erfurth et al.
OPHTHALMOLOGY (2014)
A Randomized Clinical Trial of Intravitreal Bevacizumab versus Intravitreal Dexamethasone for Diabetic Macular Edema The BEVORDEX Study
Mark C. Gillies et al.
OPHTHALMOLOGY (2014)
Intravitreal Aflibercept for Diabetic Macular Edema
Jean-Francois Korobelnik et al.
OPHTHALMOLOGY (2014)
Ranibizumab Monotherapy or Combined with Laser versus Laser Monotherapy for Diabetic Macular Edema: A Meta-Analysis of Randomized Controlled Trials
Guohai Chen et al.
PLOS ONE (2014)
The Effect of Photocoagulation in Ischemic Areas to Prevent Recurrence of Diabetic Macular Edema After Intravitreal Bevacizumab Injection
Yoshihiro Takamura et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2014)
An open-label, one-year, noncomparative study to evaluate the safety and tolerability of intravitreal pegaptanib sodium in patients with diabetic macular edema
Sobha Sivaprasad et al.
CLINICAL OPHTHALMOLOGY (2014)
Identification of Circulating Melanoma Cells in Uveal Melanoma Patients by Dual-Marker Immunoenrichment
Ayseguel Tura et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2014)
Expression of Neonatal Fc Receptor in the Eye
Michael B. Powner et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2014)
Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema
Claus Zehetner et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2013)
VEGF Secreted by Hypoxic Muller Cells Induces MMP-2 Expression and Activity in Endothelial Cells to Promote Retinal Neovascularization in Proliferative Diabetic Retinopathy
Murilo Rodrigues et al.
DIABETES (2013)
Risk factors associated with diabetic macular edema
Thuan M. Diep et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2013)
Effects of bevacizumab in retina and choroid after intravitreal injection into monkey eyes
Ulrich Schraermeyer et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2013)
Hyperactivation of retina by light in mice leads to photoreceptor cell death mediated by VEGF and retinal pigment epithelium permeability
M. Cachafeiro et al.
CELL DEATH & DISEASE (2013)
Intravitreal Fasudil Combined With Bevacizumab for Persistent Diabetic Macular Edema A Novel Treatment
Hamid Ahmadieh et al.
JAMA OPHTHALMOLOGY (2013)
Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab
Nicholas Papadopoulos et al.
ANGIOGENESIS (2012)
Factors Associated With Changes in Visual Acuity and Central Subfield Thickness at 1 Year After Treatment for Diabetic Macular Edema With Ranibizumab
Susan B. Bressler et al.
ARCHIVES OF OPHTHALMOLOGY (2012)
Effects of bevacizumab on neuronal viability of retinal ganglion cells in rats
Maria Rosaria Romano et al.
BRAIN RESEARCH (2012)
The vascular endothelial growth factor (VEGF)-E encoded by orf virus regulates keratinocyte proliferation and migration and promotes epidermal regeneration
Lyn M. Wise et al.
CELLULAR MICROBIOLOGY (2012)
Ranibizumab for Diabetic Macular Edema Results from 2 Phase III Randomized Trials: RISE and RIDE
Quan Dong Nguyen et al.
OPHTHALMOLOGY (2012)
TWO-YEAR RESULTS OF A RANDOMIZED TRIAL OF INTRAVITREAL BEVACIZUMAB ALONE OR COMBINED WITH TRIAMCINOLONE VERSUS LASER IN DIABETIC MACULAR EDEMA
Masoud Soheilian et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2012)
The relative clinical effectiveness of ranibizumab and bevacizumab in diabetic macular oedema: an indirect comparison in a systematic review
John A. Ford et al.
BMJ-BRITISH MEDICAL JOURNAL (2012)
Retinal Nerve Fiber Layer Thickness Changes in Patients with Age-Related Macular Degeneration Treated with Intravitreal Ranibizumab
Jose M. Martinez-de-la-Casa et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2012)
Intravitreal Anti-VEGF Therapy Blocks Inflammatory Cell Infiltration and Re-Entry into the Circulation in Retinal Angiogenesis
Shintaro Nakao et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2012)
Changes in Aqueous Concentrations of Various Cytokines After Intravitreal Triamcinolone Versus Bevacizumab for Diabetic Macular Edema
Hee Jin Sohn et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2011)
Ischaemia-induced retinal neovascularisation and diabetic retinopathy in mice with conditional knockout of hypoxia-inducible factor-1 in retinal Muller cells
M. Lin et al.
DIABETOLOGIA (2011)
Comparison of Intravitreal Bevacizumab and Ranibizumab Treatment for Diabetic Macular Edema
Banu Turgut Ozturk et al.
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS (2011)
Roles of IL-8 in Ocular Inflammations: A Review
Hassan Ghasemi et al.
OCULAR IMMUNOLOGY AND INFLAMMATION (2011)
The Effect of Adjunctive Intravitreal Bevacizumab for Preventing Postvitrectomy Hemorrhage in Proliferative Diabetic Retinopathy
Jeeyun Ahn et al.
OPHTHALMOLOGY (2011)
INTRAVITREAL TUMOR NECROSIS FACTOR INHIBITORS IN THE TREATMENT OF REFRACTORY DIABETIC MACULAR EDEMA A Pilot Study From the Pan-American Collaborative Retina Study Group
Lihteh Wu et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2011)
Effect of Intravitreal Bevacizumab on Vascular Endothelial Growth Factor Expression in Patients with Proliferative Diabetic Retinopathy
Eun Jee Chung et al.
YONSEI MEDICAL JOURNAL (2011)
A Potential Role for Angiopoietin 2 in the Regulation of the Blood-Retinal Barrier in Diabetic Retinopathy
Sampathkumar Rangasamy et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2011)
Toxicity testing of the VEGF inhibitors bevacizumab, ranibizumab and pegaptanib in rats both with and without prior retinal ganglion cell damage
Sebastian Thaler et al.
ACTA OPHTHALMOLOGICA (2010)
Research and development of next generation of antibody-based therapeutics
Jing Li et al.
ACTA PHARMACOLOGICA SINICA (2010)
Stromal Cell-Derived Factor-1 Is Essential for Photoreceptor Cell Protection in Retinal Detachment
Hiroki Otsuka et al.
AMERICAN JOURNAL OF PATHOLOGY (2010)
Muller Cell-Derived VEGF Is Essential for Diabetes-Induced Retinal Inflammation and Vascular Leakage
Juanjuan Wang et al.
DIABETES (2010)
Infliximab for Diabetic Macular Edema Refractory to Laser Photocoagulation A randomized, double-blind, placebo-controlled, crossover, 32-week study
Petros P. Sfikakis et al.
DIABETES CARE (2010)
Full-thickness macular hole after intravitreal injection of ranibizumab in a patient with retinal pigment epithelium detachment and tear
Vlassis Grigoropoulos et al.
EUROPEAN JOURNAL OF OPHTHALMOLOGY (2010)
Sequential anterior ischemic optic neuropathy and central retinal artery and vein occlusion after ranibizumab for diabetic macular edema
Maurizio Battaglia Parodi et al.
EUROPEAN JOURNAL OF OPHTHALMOLOGY (2010)
Anterior ischemic optic neuropathy following intravitreal bevacizumab
Jane Y. Huang et al.
JAPANESE JOURNAL OF OPHTHALMOLOGY (2010)
Matrix metalloproteinase-2 in the development of diabetic retinopathy and mitochondrial dysfunction
Ghulam Mohammad et al.
LABORATORY INVESTIGATION (2010)
Features of Optical Coherence Tomography Are Predictive of Visual Outcomes after Intravitreal Bevacizumab Injection for Diabetic Macular Edema
Mi In Roh et al.
OPHTHALMOLOGICA (2010)
ANGIOGENIC AND INFLAMMATORY MARKERS IN THE INTRAOCULAR FLUID OF EYES WITH DIABETIC MACULAR EDEMA AND INFLUENCE OF THERAPY WITH BEVACIZUMAB
Marion Funk et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2010)
Minimal Effects of VEGF and Anti-VEGF Drugs on the Permeability or Selectivity of RPE Tight Junctions
Shaomin Peng et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2010)
Alterations in the Intraocular Cytokine Milieu after Intravitreal Bevacizumab
Farzin Forooghian et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2010)
Monoclonal antibodies: versatile platforms for cancer immunotherapy
Louis M. Weiner et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Intravitreal injection of pegaptanib sodium for proliferative diabetic retinopathy
V. H. Gonzalez et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2009)
Bilateral improvement of persistent diffuse diabetic macular oedema after unilateral intravitreal bevacizumab (Avastin) injection
R. Scartozzi et al.
EYE (2009)
The effect of intravitreal bevacizumab (avastin) administration on systemic hypertension
R. Rasier et al.
EYE (2009)
Intravitreal VEGF levels in uveitis patients and treatment of uveitic macular oedema with intravitreal bevacizumab
K. Weiss et al.
EYE (2009)
Snake Venom Vascular Endothelial Growth Factors (VEGF-Fs) Exclusively Vary Their Structures and Functions among Species
Yasuo Yamazaki et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Evaluation of Differential Toxicity of Varying Doses of Bevacizumab on Retinal Ganglion Cells, Retinal Pigment Epithelial Cells, and Vascular Endothelial Growth Factor-Enriched Choroidal Endothelial Cells
Vikram S. Brar et al.
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS (2009)
OPTIC NEUROPATHY IN PATIENTS WITH GLIOBLASTOMA RECEIVING BEVACIZUMAB
J. H. Sherman et al.
NEUROLOGY (2009)
Vitreous Mediators after Intravitreal Bevacizumab or Triamcinolone Acetonide in Eyes with Proliferative Diabetic Retinopathy
Noboru Arimura et al.
OPHTHALMOLOGY (2009)
Randomized Trial of Intravitreal Bevacizumab Alone or Combined with Triamcinolone versus Macular Photocoagulation in Diabetic Macular Edema
Masoud Soheilian et al.
OPHTHALMOLOGY (2009)
Microincision Vitrectomy Surgery and Intravitreal Bevacizumab as a Surgical Adjunct to Treat Diabetic Traction Retinal Detachment
Yusuke Oshima et al.
OPHTHALMOLOGY (2009)
BEVACIZUMAB IS NOT TOXIC TO RETINAL GANGLION CELLS AFTER REPEATED INTRAVITREAL INJECTION
Cheng-Kuo Cheng et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2009)
Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab
S. J. Bakri et al.
EYE (2009)
Dexamethasone inhibits leukocyte accumulation and vascular permeability in retina of streptozotocin-induced diabetic rats via reducing vascular endothelial growth factor and intercellular adhesion molecule-1 expression
Kang Wang et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2008)
5-lipoxygenase, but not 12/15-lipoxygenase, contributes to degeneration of retinal capillaries in a mouse model of diabetic retinopathy
Rose A. Gubitosi-Klug et al.
DIABETES (2008)
Short-term complications of intravitreal injections of triamcinolone and bevacizumab
J. B. Jonas et al.
EYE (2008)
Endogenous VEGF Is Required for Visual Function: Evidence for a Survival Role on Muller Cells and Photoreceptors
Magali Saint-Geniez et al.
PLOS ONE (2008)
INCIDENCE OF ENDOPHTHALMITIS RELATED TO INTRAVITREAL INJECTION OF BEVACIZUMAB AND RANIBIZUMAB
David R. Fintak et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2008)
Effects of bevacizumab (Avastin) on retinal cells in organotypic culture
Stefanie Kaempf et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2008)
Mapping of the neonatal Fc receptor in the rodent eye
Hyuncheol Kim et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2008)
Impact of intravitreal injection of Bevacizumab (Avastin) on rabbits choroid and retina
Sherif Karawya et al.
MIDDLE EAST AFRICAN JOURNAL OF OPHTHALMOLOGY (2008)
VEGF-A splicing: the key to anti-angiogenic therapeutics?
Steven J. Harper et al.
NATURE REVIEWS CANCER (2008)
Effect of anti-VEGF antibody on retinal ganglion cells in rats
Aya Iriyama et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2007)
Retinal pigment epithelial tear after intravitreal ranibizumab
Sophie J. Bakri et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2007)
Acute endophthalmitis following intravitreal bevacizumab (Avastin) injection
F. B. Aggio et al.
EYE (2007)
Impaired pericyte recruitment and abnormal retinal angiogenesis as a result of angiopoietin-2 overexpression
Yuxi Feng et al.
THROMBOSIS AND HAEMOSTASIS (2007)
Deletion of smooth muscle α-actin alters blood-retina barrier permeability and retinal function
JJ Tomasek et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2006)
Diabetic macular edema associated with glitazone use
Edwin H. Ryan et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2006)
TGFβ pathobiology in the eye
S Saika
LABORATORY INVESTIGATION (2006)
A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema
ET Cunningham et al.
OPHTHALMOLOGY (2005)
Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina
H Tamura et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2005)
Regression of sight-threatening macular edema in type 2 diabetes following treatment with the anti-tumor necrosis factor monoclonal antibody infliximab
PP Sfikakis et al.
DIABETES CARE (2005)
Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown
JL Edelman et al.
EXPERIMENTAL EYE RESEARCH (2005)
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
N Ferrara et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
Angiopoietin-2 causes pericyte dropout in the normal retina - Evidence for involvement in diabetic retinopathy
HP Hammes et al.
DIABETES (2004)
Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies
G Bocci et al.
CANCER RESEARCH (2004)
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
JC Yang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis
M Skobe et al.
NATURE MEDICINE (2001)
Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer
MS Gordon et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
分享论文
